Your cart
لا توجد أية عناصر أخرى في عربة التسوق
• Cognitive impairment in organic brain damage, including the consequences of neuroinfections, traumatic brain injuries, and neurotic disorders;
• Extrapyramidal hyperkinesis, in patients with hereditary diseases of the nervous system in combination with ongoing therapy;
• As a corrector for the side effects of neuroleptic drugs, for neuroleptic extrapyramidal syndrome (hyperkinetic and akinetic), as part of combination therapy for cerebral organic insufficiency in patients with schizophrenia;
• Epilepsy with mental retardation in combination therapy with anticonvulsants;
• Psychoemotional overload, decreased mental and physical performance, to improve concentration and memory;
• Neurogenic urination disorders (pollakiuria, urge to urinate, urge to urinate, enuresis);
• Children with developmental delays (mental, speech, motor, or a combination of these), including those associated with perinatal encephalopathy and children with various forms of cerebral palsy;
• Children with hyperkinetic disorders (attention deficit hyperactivity disorder)
• Children with neurosis-like conditions (tics; stuttering, primarily the clonic form)
Orally, 15-30 minutes after meals.
A single dose for adults is usually 250-1000 mg, for children - 250-500 mg; the daily dose for adults is 1500 mg to 3000 mg, for children - 750 mg to 3000 mg. The course of treatment is 1 to 4 months, in some cases up to 6 months. A repeat course of treatment may be administered after 3-6 months. For cognitive impairment associated with organic brain damage, including the consequences of neuroinfections, traumatic brain injury, and neurotic disorders: 250 mg 3-4 times daily.
For extrapyramidal hyperkinesis in patients with hereditary diseases of the nervous system, in combination with ongoing therapy: at a dose of 500 mg to 3000 mg per day. The course of treatment is up to 4 months or more.
As a corrector for the side effects of neuroleptic drugs, for neuroleptic extrapyramidal syndrome (hyperkinetic and akinetic), and as part of combination therapy for cerebral organic insufficiency in patients with schizophrenia: for adults - at a dose of 500 mg to 1000 mg 3 times daily; for children - at a dose of 250 mg to 500 mg 3-4 times daily.
The course of treatment is 1-3 months.
For epilepsy with mental retardation, in combination with anticonvulsants: adults - 500 mg to 1000 mg 3 times daily; children - 250 mg to 500 mg 3-4 times daily.
Treatment course: up to 6 months.
For psychoemotional overload, decreased mental and physical performance, and to improve concentration and memory: 250 mg 3 times daily.
For neurogenic urination disorders: adults - 500 mg to 1000 mg 2-3 times daily; children - 250 mg to 500 mg 3 times daily (daily dose: 25-50 mg/kg). Treatment course: 1-3 months.
For children with various nervous system pathologies, depending on age, the recommended dose is 1000-3000 mg per day. The drug administration strategy is to increase the dose over 7-12 days, maintain the maximum dose for 15-40 days, and gradually reduce the dose until discontinuing Gopantam® over 7-8 days. The interval between courses of Gopantam®, as with any other nootropic agent, is 1 to 3 months.
For children with developmental delays: 500 mg 3-4 times daily. The treatment course is 23 months.
For children with attention deficit hyperactivity disorder: Depending on body weight, the drug is prescribed at an average therapeutic dose of 30 mg/kg per day, morning and afternoon. The optimal dose is determined individually for each patient by titrating the dose gradually over the first 5-7 days. The treatment course is 3-4 months.
For children with neurosis-like conditions (tics; stuttering, primarily the clonic form): 250 mg to 500 mg 3-6 times daily.
Treatment duration: 1-4 months.
Given the drug's nootropic effect, it is preferably taken in the morning and afternoon (before 5 PM).
The drug is used in children over 3 years of age. For younger children, the pediatric formulation is recommended.
Tap to zoom
